Navigation Links
Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Date:6/4/2008

SEATTLE, June 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Kendall Mohler, co-founder and senior vice president of research and development, is scheduled to present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference on June 12 at 10 a.m. EDT. This conference will be held at the New York Palace Hotel in New York City. The presentation will be available via audio webcast at http://www.wsw.com/webcast/needham25/trbn/ and will be available in the investors section of Trubion's website, investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Announces Presentations at April/May Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
3. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
7. Onyx Pharmaceuticals to Present at Goldman Sachs 29th Annual Global Healthcare Conference
8. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
9. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
10. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
11. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , May 23, 2017 As Ebola resurfaces ... with four deaths and 20 suspected cases now reported, a ... the PubMed database, showed a correlation between the 2014 and ... Replikin counts rose sharply in 2012-13, which preceded the 2014 ... in the Ebola gene Replikin counts in 2014-15, which again ...
(Date:5/23/2017)... ... 22, 2017 , ... NetDimensions has been ranked as a ... for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess ... against those strategies. NetDimensionsā€™ ranking as a Leader due to its strengths in: ...
(Date:5/23/2017)... San Diego, CA (PRWEB) , ... May 23, 2017 , ... ... extracellular matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and ... economic impact of biofilms is in the tens of billions of dollars per year, ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology ... B2 at the Association for Pathology Informatics Annual Summit at the ... demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):